Home > Healthcare > Medical Devices > Diagnostic Devices > Non-Invasive Prenatal Testing Market

Non-Invasive Prenatal Testing Market Share

Report ID: GMI10245
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Non-Invasive Prenatal Testing Market Share

The non-invasive prenatal testing industry is experiencing significant growth due to rising global prevalence of respiratory disorders, fuelled by factors such as aging populations and lifestyle changes. Key players, including healthcare providers, and medical device manufacturers, drive innovation with technologies. Initiatives in advanced devices, systems, consumables and personalized healthcare are reshaping the landscape, emphasizing early detection and tailored treatment approaches. As demand for accurate prenatal testing continues to escalate, market expansion, collaboration, and investment in advanced solutions are key strategies for industry players.

Non-Invasive Prenatal Testing Market Companies

Prominent players operating in the non-invasive prenatal testing industry include:

Agilent Technologies, Inc.
BGI
Centogene N.V.
Eurofins LifeCodexx GmbH
F. Hoffmann-La Roche Ltd.
IGENOMIX
Illumina, Inc.
Labcorp
MedGenome Labs Ltd.
Myriad Women’s Health, Inc.
Natera, Inc.
Pacific Biosciences
PerkinElmer Inc.
Progenity, Inc.
Quest Diagnostics, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Non-invasive prenatal testing industry size was USD 4.8 billion in 2023 and is projected to expand at 12.4% CAGR from 2024 to 2032, due to the high incidence rate of genetic disorders.

The consumables & reagents product segment in the non-invasive prenatal testing industry recorded USD 2.2 billion in 2023 and is estimated to witness substantial growth between 2024 and 2032, as these are required for every test performed.

The NGS technology segment in the non-invasive prenatal testing industry recorded 44.6% share in 2023 as it allows for comprehensive genetic analysis for providing high accuracy and sensitivity in detecting chromosomal abnormalities and genetic conditions.

North America on-invasive prenatal testing market size recorded USD 1.9 billion in 2023 and is projected to expand at 11.6% CAGR between 2024 and 2032, owing to the increasing awareness among expectant parents and healthcare providers.